Lifecycle of an Imaging Biomarker

TriMed Staff | | Health Imaging | Diagnostic Imaging
Lifecycle of an Imaging Biomarker: From Validation to Dissemination

Thursday, Dec. 2, 10:30 AM - 12:00 PM

Speakers are sharing perspectives on the use of quantitative imaging as a biomarker in clinical trials and providing examples of best practices.

The speakers are:
  • Jeffrey T. Yap, PhD, senior diagnostic physicist, Dana-Farber Cancer Institute in Boston;
  • Neil M. Rofsky, MD, chief, MRI, Beth Israel Deaconess Medical Center in Boston;
  • Simon K. Warfield, PhD, director, computational radiology laboratory, Children’s Hospital in Boston.

TriMed Staff

Related Content

AI rules out abnormal findings on chest X-rays, significantly reducing workloads
Older adults among the walking wounded with incident TBI
Philips moves digital pathology to the cloud with AWS
PHOTO GALLERY: What does fetal medical imaging look like?
Speaker laments radiology’s major contribution to climate change
Radiologist accuracy takes a hit overnight, especially with advanced imaging exams

Around the web

Radiology Business
The biggest challenges facing radiology business managers in 2025

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.